(NASDAQ: OCGN) has announced a significant development in its efforts to treat Stargardt disease, as the Data and Safety Monitoring Board (DSMB) has greenlit the enrollment for the second phase of ...

Using a gene signature technique to tailor chemotherapy for patients with early triple negative breast cancer shows promise ...

Gov. Kathy Hochul announced plans to build a $430 million New York BioGenesis Park — a cell and gene therapy lab — in Lake ...

The pharma market shows promise as gene therapy gains momentum through rapid advancements that address complex diseases and ...

The team has developed synthetic 'DNA switches' that can control genes in certain cells. It's believed the technology could ...

Sangamo's phase 1/2 STARR study data using isaralgagene civaparvovec targeting patients with Fabry Disease is expected in H1 2025. Learn more on SGMO stock here.

Researchers have used artificial intelligence to design thousands of new DNA switches that can precisely control the expression of a gene in different cell types. Their new approach opens the ...

Researchers used AI to design thousands of new DNA switches that can precisely control the expression of a gene in different cell types.

Yale spinout Modifi agreed to sell to Merck for $30 million upfront. Elsewhere, Sangamo plotted a much faster path to market ...

Shares of Editas Medicine EDIT plunged 12.5% on Tuesday after announcing that it is seeking a global partner to advance its ...

By squeezing Regeneron’s Eylea, eye disease drug Vabysmo has become one of the biggest growth drivers for Roche. | Despite ...